EPCT Insider Trading Activity and SEC Form 4 Filings
EPCT insider trading summary
No open-market insider purchases or sales of Epicept Corp (EPCT) have been reported on SEC Form 4 in the past 12 months.
Latest EPCT insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 13, 2007 | Robert W Cook | CFO-SVP, Finance & Admin. | Buy | $7K (5,000 @ $1.35) |
| Dec 13, 2007 | Robert G Savage | Director | Buy | $7K (5,000 @ $1.44) |
| Dec 13, 2007 | Robert G Savage | Director | Buy | $7K (5,000 @ $1.35) |
| Dec 13, 2007 | John V Talley | President, CEO & Director | Buy | $21K (15,000 @ $1.40) |
| Dec 13, 2007 | Robert G Savage | Director | Buy | $4K (3,000 @ $1.36) |
| Dec 13, 2007 | Robert G Savage | Director | Buy | $7K (5,000 @ $1.42) |
| Dec 13, 2007 | Robert G Savage | Director | Buy | $7K (5,000 @ $1.35) |
| Dec 13, 2007 | Robert G Savage | Director | Buy | $9K (7,000 @ $1.35) |
| Dec 12, 2007 | Oliver Wiedemann | Managing Director-See Remarks | Buy | $7K (5,000 @ $1.40) |
| Dec 12, 2007 | Dileep Bhagwat | SVP-Pharmaceutical Development | Buy | $4K (2,500 @ $1.42) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.